Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT142 in CLDN6-positive Advanced Solid Tumors
NCT05262530Phase 2Terminated
- Sponsor
- BioNTech SE
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Lipid-based Nanoparticles, Bispecific Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of BNT142 in solid tumor, ovarian cancer, non-small cell lung cancer (NSCLC) and 2 more, sponsored by BioNTech SE. Primary endpoints: Treatment Emergent Adverse Events, Dose reductions and discontinuation due to TEAEs and 2 more. Started Mar 2022; status: terminated.
02
Drugs
BNT142
03
Conditions
solid tumorovarian cancernon-small cell lung cancer (NSCLC)testicular cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT05262530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262530.